Elvitegravir
lvitegravir (EVG) is an investigational new drug for the treatment of HIV infection. It acts as an integrase inhibitor. It is undergoing Phase III clinical trial[1] conducted by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2005.[2][3]...
